Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 52 publications
ELAINE 3: phase 3 study of lasofoxifene plus abemaciclib to treat ER+/HER2-, ESR1-mutated, metastatic breast cancer.
Journal: Future oncology (London, England)
Published: April 13, 2025
Effects of Lasofoxifene Versus Fulvestrant on Vaginal and Vulvar Symptoms in Patients With ESR1-Mutated, ER+/HER2-, Metastatic Breast Cancer From the ELAINE 1 Study.
Journal: Clinical breast cancer
Published: July 19, 2024
Oral lasofoxifene's effects on moderate to severe vaginal atrophy in postmenopausal women: two phase 3, randomized, controlled trials.
Journal: Menopause (New York, N.Y.)
Published: April 23, 2024
Lasofoxifene versus fulvestrant for ER+/HER2- metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 25, 2023
Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2- breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: April 25, 2023
Learning from the challenges of undertaking an evaluation of a multi-partner housing support initiative delivered within a hospital setting.
Journal: Public health in practice (Oxford, England)
Published: May 20, 2022
Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide.
Journal: Journal of women's health (2002)
Published: March 01, 2022
Safety Profile of Bremelanotide Across the Clinical Development Program.
Journal: Journal of women's health (2002)
Published: February 11, 2022
Variability in Contraceptive Clinical Trial Design and the Challenges in Making Comparisons Across Trials.
Journal: Advances in therapy
Published: August 04, 2021
Failure of a Meta-analysis: A Commentary on Glen Spielmans's "Re-Analyzing Phase III Bremelanotide Trials for 'Hypoactive Sexual Desire Disorder in Women'".
Journal: Journal of sex research
Published: April 09, 2021
Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder.
Journal: Obstetrics and gynecology
Published: October 11, 2019
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials.
Journal: Obstetrics and gynecology
Published: October 11, 2019
Last Updated: 09/26/2026